作者：
Kensuke,Sakuma [1]
;
Noriko,Tsubooka-Yamazoe [2]
;
Kiyohiro,Hashimoto [3]
;
Nozomu,Sakai [4]
;
Shinya,Asano [5]
;
Saori,Watanabe-Matsumoto [6]
;
Takeshi,Watanabe [7]
;
Bunnai,Saito [4]
;
Hirokazu,Matsumoto [8]
;
Hikaru,Ueno [5]
;
Ryo,Ito [6]
;
Taro,Toyoda [4]
作者单位：
iPSC-Derived Pancreatic Islet Cell (iPIC) Therapy Department, Orizuru Therapeutics Inc., Fujisawa, Kanagawa, 251-8555, Japan. kensuke.sakuma@orizuru-therapeutics.com.
[1]
Takeda-CiRA Joint Program for iPS Cell Applications (T-CiRA), Fujisawa, Kanagawa, 251-8555, Japan. kensuke.sakuma@orizuru-therapeutics.com.
[2]
iPSC-Derived Pancreatic Islet Cell (iPIC) Therapy Department, Orizuru Therapeutics Inc., Fujisawa, Kanagawa, 251-8555, Japan.
[3]
Takeda-CiRA Joint Program for iPS Cell Applications (T-CiRA), Fujisawa, Kanagawa, 251-8555, Japan.
[4]
Drug Safety Research and Evaluation Group, Takeda Pharmaceutical Company Limited, Kanagawa, 251-8555, Japan.
[5]
Drug Discovery Sciences, Takeda Pharmaceutical Company Limited, Kanagawa, 251-8555, Japan.
[6]
Integrated & Translational Science, Axcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa, 251-8555, Japan.
[7]
Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, 606-8507, Japan.
[8]
T-CiRA Discovery and Innovation, Takeda Pharmaceutical Company Limited, Kanagawa, 251-8555, Japan.
[9]
Takeda-CiRA Joint Program for iPS Cell Applications (T-CiRA), Fujisawa, Kanagawa, 251-8555, Japan. t.toyoda@cira.kyoto-u.ac.jp.
[10]
Department of Life Science Frontiers, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, 606-8507, Japan. t.toyoda@cira.kyoto-u.ac.jp.
[11]
DOI
10.1186/s13287-022-03220-4
PMID
36600289
发布时间
2023-02-17
换一批
换一批
